Daily consumption of curcumin over a 3-month period of up to 12 grams was found to be safe in humans , In Phase I clinical trials , dietary curcumin was shown to exhibit poor bioavailability , exhibited by rapid metabolism , low levels in p
In Phase I clinical trials , dietary curcumin showed low levels in plasma and tissues , and extensive rapid excretion .